ALXN

Alexion Pharmaceuticals, Inc. News Headlines

$173.27
*  
1.205
0.69%
Get ALXN Alerts
*Delayed - data as of Oct. 22, 2014  -  Find a broker to begin trading ALXN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
6/17/2014 5:20:00 PM - Zacks.com


Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog
6/17/2014 5:00:00 PM - Zacks.com


Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog
6/16/2014 5:10:00 PM - Zacks.com


Alexion Pharmaceuticals: 4 Different Insiders Have Sold Shares During The Last 30 Days
6/16/2014 10:35:00 AM - Seeking Alpha


Shire to Conduct Trials on Vyvanse on FDA's Request - Analyst Blog
6/13/2014 6:25:00 PM - Zacks.com


AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal - Analyst Blog
6/13/2014 6:20:00 PM - Zacks.com


Vertex Pharmaceuticals' New Kalydeco Data Out - Analyst Blog
6/13/2014 4:10:00 PM - Zacks.com


Stunning Potential For Upside In Canadian Biotech: Brian Bloom
6/13/2014 10:15:00 AM - Seeking Alpha


Bayer Looking to Expand Eylea's Label - Analyst Blog
6/12/2014 5:00:00 PM - Zacks.com


Roche's HPV Test Approved in Canada - Analyst Blog
6/12/2014 11:40:00 AM - Zacks.com


Encouraging Long-Term Data on Celgene's Otezla - Analyst Blog
6/12/2014 11:30:00 AM - Zacks.com


Alkermes Progresses with its Late Stage Candidate - Analyst Blog
6/11/2014 5:00:00 PM - Zacks.com


NPS Pharma's Natpara Likely to be Reviewed in September - Analyst Blog
6/11/2014 4:30:00 PM - Zacks.com


Allergan Rejects Valeant's Proposal Yet Again - Analyst Blog
6/11/2014 11:50:00 AM - Zacks.com


PDL BioPharma Views Lower Q2 Revenues - Analyst Blog
6/11/2014 11:27:00 AM - Zacks.com


Immunomedics' IMMU-132 Gets Orphan Drug Status - Analyst Blog
6/10/2014 6:10:00 PM - Zacks.com


Valeant's Jublia Approved in the U.S. - Analyst Blog
6/10/2014 5:50:00 PM - Zacks.com


Dendreon's CEO Departs at Critical Juncture - Analyst Blog
6/10/2014 5:20:00 PM - Zacks.com


Agios Initiates Trial on AG-348 - Analyst Blog
6/10/2014 4:35:00 PM - Zacks.com


GW Pharma Gets Fast-Track Designation for Epidiolex - Analyst Blog
6/9/2014 5:40:00 PM - Zacks.com


Pipeline Progress at GlaxoSmithKline - Analyst Blog
6/6/2014 11:26:00 AM - Zacks.com


MannKind Hits 52-Week High - Analyst Blog
6/6/2014 8:00:00 AM - Zacks.com


Positive Phase IIb Data from Jazz Pharma - Analyst Blog
6/5/2014 6:56:00 PM - Zacks.com


Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog
6/5/2014 6:26:00 PM - Zacks.com


Positive Data on Vertex Pharma's Kalydeco - Analyst Blog
6/5/2014 4:45:00 PM - Zacks.com